What does Sagimet Biosciences Inc. do?
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral,…
What is Sagimet Biosciences Inc.'s P/E and P/B ratio?
Sagimet Biosciences Inc. has a P/E ratio of -7.8 and a P/B ratio of 2.75.
What is Sagimet Biosciences Inc.'s debt-to-equity ratio?
Sagimet Biosciences Inc. has a debt-to-equity ratio of 0.01.
How much does Sagimet Biosciences Inc. owe compared with what it owns?
Sagimet Biosciences Inc. owes $0.03 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Sagimet Biosciences Inc.'s Positivity rank?
Sagimet Biosciences Inc. is ranked #5,104 of 6,774 companies globally and #2,713 of 4,000 in United States on PositoAI, with a Positivity Score of 18,380.
Does Sagimet Biosciences Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Sagimet Biosciences Inc..
Where can I read the latest news about Sagimet Biosciences Inc.?
Recent headlines about Sagimet Biosciences Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Sagimet Biosciences Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Sagimet Biosciences Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.